ARALEZ PHARMACEUTICALS INC. Research and Development Expense
ARALEZ PHARMACEUTICALS INC. reported Research and Development Expense of $37.00 thousand for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-08.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2018-05-08
- ARALEZ PHARMACEUTICALS INC. research and development expense for the quarter ending 2018-03-31 was $37.00K, a 60.64% decline year-over-year.
- ARALEZ PHARMACEUTICALS INC. research and development expense for the quarter ending 2017-12-31 was $766.00K, a 15.73% decline year-over-year.
- ARALEZ PHARMACEUTICALS INC. research and development expense for the quarter ending 2017-09-30 was $736.00K, a 63.87% decline year-over-year.
- ARALEZ PHARMACEUTICALS INC. research and development expense for the quarter ending 2017-06-30 was $728.00K, a 50.61% decline year-over-year.
- ARALEZ PHARMACEUTICALS INC. research and development expense for fiscal 2017 was $2.32M, a 73.69% decline from fiscal 2016.
- ARALEZ PHARMACEUTICALS INC. research and development expense for fiscal 2016 was $8.83M, a 3.76% increase from fiscal 2015.
- ARALEZ PHARMACEUTICALS INC. research and development expense for fiscal 2015 was $8.51M, a 48.29% increase from fiscal 2014.
- ARALEZ PHARMACEUTICALS INC. research and development expense for fiscal 2014 was $5.74M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2018-03-31 | $37.00K 10-Q · filed 2018-05-08 | $803.00K derived: sum of 2 quarters · filed 2018-05-08 | $1.54M derived: sum of 3 quarters · filed 2018-05-08 | $2.27M derived: sum of 4 quarters · filed 2018-05-08 |
| 2017-12-31 | $766.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14 | $1.50M derived: sum of 2 quarters · filed 2018-03-14 | $2.23M derived: sum of 3 quarters · filed 2018-03-14 | $2.32M 10-K · filed 2018-03-14 |
| 2017-09-30 | $736.00K 10-Q · filed 2017-11-09 | $1.46M derived: sum of 2 quarters · filed 2017-11-09 | $1.56M 10-Q · filed 2017-11-09 | $2.47M derived: sum of 4 quarters · filed 2018-05-08 |
| 2017-06-30 | $728.00K 10-Q · filed 2017-08-09 | $822.00K 10-Q · filed 2017-08-09 | $1.73M derived: sum of 3 quarters · filed 2018-05-08 | $3.77M derived: sum of 4 quarters · filed 2018-05-08 |
| 2017-03-31 | $94.00K 10-Q · filed 2018-05-08 | $1.00M derived: sum of 2 quarters · filed 2018-05-08 | $3.04M derived: sum of 3 quarters · filed 2018-05-08 | $4.51M derived: sum of 4 quarters · filed 2018-05-08 |
| 2016-12-31 | $909.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14 | $2.95M derived: sum of 2 quarters · filed 2018-03-14 | $4.42M derived: sum of 3 quarters · filed 2018-03-14 | $8.83M 10-K · filed 2018-03-14 |
| 2016-09-30 | $2.04M 10-Q · filed 2017-11-09 | $3.51M derived: sum of 2 quarters · filed 2017-11-09 | $7.92M 10-Q · filed 2017-11-09 | $11.34M derived: sum of 4 quarters · filed 2018-03-14 |
| 2016-06-30 | $1.47M 10-Q · filed 2017-08-09 | $5.89M 10-Q · filed 2017-08-09 | $9.31M derived: sum of 3 quarters · filed 2018-03-14 | $11.11M derived: sum of 4 quarters · filed 2018-03-14 |
| 2016-03-31 | $4.41M 10-Q · filed 2017-05-09 | $7.83M derived: sum of 2 quarters · filed 2018-03-14 | $9.64M derived: sum of 3 quarters · filed 2018-03-14 | $11.94M derived: sum of 4 quarters · filed 2018-03-14 |
| 2015-12-31 | $3.42M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14 | $5.23M derived: sum of 2 quarters · filed 2018-03-14 | $7.53M derived: sum of 3 quarters · filed 2018-03-14 | $8.51M 10-K · filed 2018-03-14 |
| 2015-09-30 | $1.81M 10-Q · filed 2016-11-08 | $4.11M derived: sum of 2 quarters · filed 2016-11-08 | $5.09M 10-Q · filed 2016-11-08 | |
| 2015-06-30 | $2.30M 10-Q · filed 2016-08-09 | $3.29M 10-Q · filed 2016-08-09 | ||
| 2015-03-31 | $984.00K 10-Q · filed 2016-05-10 | |||
| 2014-12-31 | $5.74M 10-K · filed 2017-03-13 |